Esperion Therapeutics (ESPR) Capital Expenditures (2012 - 2026)

Esperion Therapeutics (ESPR) posted Capital Expenditures of $189000.0 for Q1 2026, little changed on a QoQ basis from $189000.0 in Q4 2025.

Esperion Therapeutics (ESPR) Capital Expenditures (2012 - 2026) Analysis & Trends

Esperion Therapeutics' Capital Expenditures history runs 12 years deep, the most recent figure standing at $189000.0 for Q1 2026.

Quarterly Capital Expenditures changed N/A year-over-year to $189000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $378000.0 (up 54.92% YoY) and the FY2025 annual result came in at $189000.0, down 40.38% from the prior year.
Capital Expenditures was $189000.0 for Q1 2026 at Esperion Therapeutics, roughly flat from $189000.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $189000.0 in Q4 2025 and bottomed at $73000.0 in Q1 2024.
A 3-year average of $139000.0 and a median of $150000.0 in 2024 frame the typical range for Capital Expenditures.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	168.00 Mn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	110.00 Mn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	1.95 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	99.60 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	39.90 Mn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	1.40 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	51.00 Mn
10	Esperion Therapeutics	799.30 Mn	643.14 Mn	45.53 Mn	189,000.00

Download Data